Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Plasma CXCL9 and CXCL10 at allograft injury predict chronic lung allograft dysfunction.

Publication ,  Journal Article
Shino, MY; Todd, JL; Neely, ML; Kirchner, J; Frankel, CW; Snyder, LD; Pavlisko, EN; Fishbein, GA; Schaenman, JM; Mason, K; Kesler, K; Budev, M ...
Published in: Am J Transplant
September 2022

Histopathologic lung allograft injuries are putative harbingers for chronic lung allograft dysfunction (CLAD). However, the mechanisms responsible are not well understood. CXCL9 and CXCL10 are potent chemoattractants of mononuclear cells and potential propagators of allograft injury. We hypothesized that these chemokines would be quantifiable in plasma, and would associate with subsequent CLAD development. In this prospective multicenter study, we evaluated 721 plasma samples for CXCL9/CXCL10 levels from 184 participants at the time of transbronchial biopsies during their first-year post-transplantation. We determined the association between plasma chemokines, histopathologic injury, and CLAD risk using Cox proportional hazards models. We also evaluated CXCL9/CXCL10 levels in bronchoalveolar lavage (BAL) fluid and compared plasma to BAL with respect to CLAD risk. Plasma CXCL9/CXCL10 levels were elevated during the injury patterns associated with CLAD, acute rejection, and acute lung injury, with a dose-response relationship between chemokine levels and CLAD risk. Importantly, there were strong interactions between injury and plasma CXCL9/CXCL10, where histopathologic injury associated with CLAD only in the presence of elevated plasma chemokines. We observed similar associations and interactions with BAL CXCL9/CXCL10 levels. Elevated plasma CXCL9/CXCL10 during allograft injury may contribute to CLAD pathogenesis and has potential as a minimally invasive immune monitoring biomarker.

Duke Scholars

Published In

Am J Transplant

DOI

EISSN

1600-6143

Publication Date

September 2022

Volume

22

Issue

9

Start / End Page

2169 / 2179

Location

United States

Related Subject Headings

  • Surgery
  • Prospective Studies
  • Lung Transplantation
  • Lung
  • Humans
  • Graft vs Host Disease
  • Graft Rejection
  • Chemokine CXCL9
  • Chemokine CXCL10
  • Biomarkers
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shino, M. Y., Todd, J. L., Neely, M. L., Kirchner, J., Frankel, C. W., Snyder, L. D., … Belperio, J. A. (2022). Plasma CXCL9 and CXCL10 at allograft injury predict chronic lung allograft dysfunction. Am J Transplant, 22(9), 2169–2179. https://doi.org/10.1111/ajt.17108
Shino, Michael Y., Jamie L. Todd, Megan L. Neely, Jerry Kirchner, Courtney W. Frankel, Laurie D. Snyder, Elizabeth N. Pavlisko, et al. “Plasma CXCL9 and CXCL10 at allograft injury predict chronic lung allograft dysfunction.Am J Transplant 22, no. 9 (September 2022): 2169–79. https://doi.org/10.1111/ajt.17108.
Shino MY, Todd JL, Neely ML, Kirchner J, Frankel CW, Snyder LD, et al. Plasma CXCL9 and CXCL10 at allograft injury predict chronic lung allograft dysfunction. Am J Transplant. 2022 Sep;22(9):2169–79.
Shino, Michael Y., et al. “Plasma CXCL9 and CXCL10 at allograft injury predict chronic lung allograft dysfunction.Am J Transplant, vol. 22, no. 9, Sept. 2022, pp. 2169–79. Pubmed, doi:10.1111/ajt.17108.
Shino MY, Todd JL, Neely ML, Kirchner J, Frankel CW, Snyder LD, Pavlisko EN, Fishbein GA, Schaenman JM, Mason K, Kesler K, Martinu T, Singer LG, Tsuang W, Budev M, Shah PD, Reynolds JM, Williams N, Robien MA, Palmer SM, Weigt SS, Belperio JA. Plasma CXCL9 and CXCL10 at allograft injury predict chronic lung allograft dysfunction. Am J Transplant. 2022 Sep;22(9):2169–2179.
Journal cover image

Published In

Am J Transplant

DOI

EISSN

1600-6143

Publication Date

September 2022

Volume

22

Issue

9

Start / End Page

2169 / 2179

Location

United States

Related Subject Headings

  • Surgery
  • Prospective Studies
  • Lung Transplantation
  • Lung
  • Humans
  • Graft vs Host Disease
  • Graft Rejection
  • Chemokine CXCL9
  • Chemokine CXCL10
  • Biomarkers